MSFT 453.9631 -2.6353% AAPL 228.225 -2.0409% NVDA 131.2 -2.75% GOOGL 187.56 -1.8935% GOOG 189.16 -1.8167% AMZN 196.37 -1.7118% META 522.38 -2.3023% AVGO 1714.64 -1.7224% TSLA 265.3951 0.811% TSM 187.5 -1.8582% LLY 937.8 -0.2107% V 261.56 -0.5475% JPM 207.67 -0.0626% UNH 505.78 0.9682% NVO 141.2 -1.0789% WMT 69.41 -1.4203% LVMUY 154.5 1.9667% XOM 112.96 0.9292% LVMHF 770.5 1.6491% MA 432.89 -0.173%

DexCom Inc

Healthcare US DXCM


Last update at 2024-07-11T14:56:00Z

Day Range


52 Week Range



  • Previous Close 110.79
  • Market Cap50656.99M
  • Volume305315
  • P/E Ratio82.71
  • Dividend Yield-%
  • EBITDA848.50M
  • Revenue TTM3801.80M
  • Revenue Per Share TTM9.83
  • Gross Profit TTM 1883.10M
  • Diluted EPS TTM1.54


Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 390.80M 173.90M 225.00M 104.20M -126.50000M
Minority interest - - - - -
Net income 341.20M 154.70M 493.60M 101.10M -127.10000M
Selling general administrative 1000.20M 810.50M 620.70M 515.70M 432.80M
Selling and marketing expenses - - - - -
Gross profit 1883.10M 1680.50M 1280.10M 931.50M 663.90M
Reconciled depreciation 155.90M 102.00M 67.10M 48.70M 29.10M
Ebit 391.20M 175.40M 299.50M 142.30M -132.90000M
Ebitda 416.90M 277.40M 382.70M 164.50M -103.80000M
Depreciation and amortization 25.70M 102.00M 83.20M 22.20M 29.10M
Non operating income net other 18.00M -3.20000M 10.20M 26.40M -
Operating income 391.20M 175.40M 299.50M 142.30M -186.30000M
Other operating expenses 2518.60M 2182.70M 1627.20M 1333.70M 1217.90M
Interest expense 18.60M 102.00M 84.70M 60.30M 22.70M
Tax provision 49.60M 19.20M -268.60000M 3.10M 0.60M
Interest income 18.00M - 16.10M 26.40M 2.40M
Net interest income -18.60000M -100.30000M -68.60000M -33.90000M -20.30000M
Extraordinary items - - - - 0.40M
Non recurring - - - - -
Other items - - - - -
Income tax expense 49.60M 19.20M -268.60000M 3.10M 0.60M
Total revenue 2909.80M 2448.50M 1926.70M 1476.00M 1031.60M
Total operating expenses 1491.90M 1414.70M 980.60M 789.20M 850.20M
Cost of revenue 1026.70M 768.00M 646.60M 544.50M 367.70M
Total other income expense net -0.40000M -1.50000M -74.50000M -38.10000M 80.10M
Discontinued operations - - - - -
Net income from continuing ops 341.20M 154.70M 493.60M 101.10M -127.10000M
Net income applicable to common shares 341.20M 154.70M 493.60M 101.10M -127.10000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 6264.50M 5391.70M 4863.60M 4290.50M 2395.00M
Intangible assets 134.50M 173.30M 42.00M - -
Earning assets - - - - -
Other current assets 49.30M 192.60M 81.60M 53.90M 30.00M
Total liab 4195.90M 3259.90M 2612.10M 2464.00M 1512.40M
Total stockholder equity 2068.60M 2131.80M 2251.50M 1826.50M 882.60M
Deferred long term liab - - - - -
Other current liab 1240.10M 134.30M 125.20M 432.10M 88.50M
Common stock 0.40M 0.40M 0.10M 0.10M 0.10M
Capital stock 0.40M 0.40M 0.10M 0.10M 0.10M
Retained earnings 1021.40M 479.90M -47.40000M -202.10000M -695.70000M
Other liab - 68.70M 90.00M 80.90M 5.70M
Good will 25.20M 25.70M 26.50M 19.30M 18.60M
Other assets - 369.30M 220.80M 237.80M 14.20M
Cash 566.30M 642.30M 1052.60M 817.60M 446.20M
Cash and equivalents - - - - -
Total current liabilities 1556.00M 1839.30M 720.80M 614.10M 360.20M
Current deferred revenue 18.40M 10.10M 2.10M 2.20M 1.70M
Net debt 2027.70M 1443.10M 769.20M 1021.90M 699.50M
Short term debt 21.10M 793.10M 20.50M 16.50M 13.60M
Short long term debt - 772.60M - - -
Short long term debt total 2594.00M 2085.40M 1821.80M 1839.50M 1145.70M
Other stockholder equity 1063.50M 1663.10M 2298.30M 2025.30M 1575.90M
Property plant equipment - 1135.60M 889.90M 515.30M 321.30M
Total current assets 4425.90M 3668.80M 3684.40M 3424.80M 1969.40M
Long term investments 38.50M - - - -
Net tangible assets - 2131.80M 2183.00M 1826.50M 864.00M
Short term investments 2157.80M 1813.90M 1678.60M 1890.10M 1087.10M
Net receivables 987.50M 713.30M 514.30M 428.50M 286.30M
Long term debt 2434.20M 1197.70M 1702.70M 1667.20M 1059.70M
Inventory 559.60M 306.70M 357.30M 234.70M 119.80M
Accounts payable 276.40M 901.80M 573.00M 163.30M 256.40M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -16.70000M -11.60000M 0.50M 3.20M 2.30M
Additional paid in capital - - - - -
Common stock total equity - 0.40M 0.10M 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - 479.90M -47.40000M -202.10000M -695.70000M
Treasury stock - - -206.20000M -100.00000M -100.00000M
Accumulated amortization - - - - -
Non currrent assets other 36.50M 47.10M 2.00M 21.40M 14.20M
Deferred long term asset charges - - - - -
Non current assets total 1838.60M 1722.90M 1179.20M 865.70M 425.60M
Capital lease obligations 159.80M 174.70M 119.10M 172.30M 100.40M
Long term debt total - 1197.70M 1702.70M 1667.20M 1059.70M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -1116.20000M -138.50000M 193.20M -807.70000M -835.20000M
Change to liabilities - 303.60M 68.40M 220.60M 125.00M
Total cashflows from investing activities - -521.50000M -216.10000M -1018.00000M -1015.20000M
Net borrowings - - - 1188.80M 906.20M
Total cash from financing activities -318.60000M -552.50000M 10.40M 912.10M 10.70M
Change to operating activities - -128.90000M -11.00000M 22.90M 6.40M
Net income 541.50M 341.20M 154.70M 493.60M 101.10M
Change in cash -75.80000M -410.30000M 235.40M 371.80M -690.70000M
Begin period cash flow 643.30M 1053.60M 818.20M 446.40M 1137.10M
End period cash flow 567.50M 643.30M 1053.60M 818.20M 446.40M
Total cash from operating activities 748.50M 669.50M 442.50M 475.60M 314.50M
Issuance of capital stock 26.60M 22.50M 20.30M 15.30M 11.90M
Depreciation 186.00M 155.90M 102.00M 67.10M 48.70M
Other cashflows from investing activities - -18.20000M -20.10000M -11.30000M -835.20000M
Dividends paid 1230.60M - - - -
Change to inventory -252.60000M 49.30M -112.20000M -114.50000M -49.10000M
Change to account receivables -260.10000M -199.90000M -75.50000M -142.30000M -60.00000M
Sale purchase of stock -688.70000M -557.70000M 20.30M 15.30M 11.90M
Other cashflows from financing activities -99.80000M -17.30000M -9.90000M 1179.40M -1.20000M
Change to netincome - 145.90M 242.30M -64.30000M 109.00M
Capital expenditures 236.60M 364.80M 389.20M 199.00M 180.00M
Change receivables - -199.90000M -75.50000M -142.30000M -60.00000M
Cash flows other operating - -126.50000M 62.80M 15.40M -9.80000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -404.50000M 236.80M 369.70M -690.00000M
Change in working capital 3.20M 27.70M -132.00000M -20.80000M 6.10M
Stock based compensation 150.80M 126.50M 113.40M 119.40M 102.70M
Other non cash items -78.00000M 39.80M 209.30M 93.60M 51.70M
Free cash flow 511.90M 304.70M 53.30M 276.60M 134.50M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DexCom Inc
2.65 2.39% 113.44 82.71 77.52 14.49 25.38 14.46 57.12
Abbott Laboratories
0.47 0.46% 103.53 37.15 23.15 4.67 4.97 4.88 19.38
Stryker Corporation
0.96 0.28% 338.30 44.07 24.94 5.51 6.12 6.05 25.73
Medtronic PLC
0.92 1.19% 77.98 26.60 15.87 3.35 2.08 3.90 14.12
Boston Scientific Corp
0.09 0.11% 77.19 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News


DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Inc

6340 Sequence Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Kevin Ronald Sayer Exec. Chairman, CEO & Pres 1958
Mr. Jereme M. Sylvain Exec. VP, CFO & Chief Accounting Officer 1980
Mr. Jacob Steven Leach Exec. VP & COO 1978
Mr. Paul R. Flynn Exec. VP of Global Revenue 1969
Mr. Sean Christensen Director of Corp. Affairs & Head of Investor Relations NA
Mr. Michael Brown Exec. VP & Chief Legal Officer 1970
Mr. Matthew Dolan Exec. VP of Strategy, Corp. Devel. & Dexcom Labs 1981
Ms. Sadie M. Stern Exec. VP & Chief HR Officer 1975
Mr. Andrew K. Balo Exec. VP of Global Medical Affairs, Access & Evidence 1948
Mr. Steven R. Pacelli Exec. VP & MD of Dexcom Ventures 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.